RNA-Interference Market Growth Analysis by 2030

The global RNA-Interference Market size is predicted to reach USD 14.7 billion with a CAGR of 15.3% by 2030.

Secure a FREE Sample!

The growing prevalence of chronic diseases globally, including cancer, cardiovascular disorders, and metabolic conditions, is driving an increased demand for RNA-interference (RNAi) as a promising therapeutic approach.

Moreover, the increasing approvals for RNAi therapies further accelerates the growth of the market by increasing confidence among stakeholders, fostering investment, and expanding accessibility to innovative treatment options for various diseases.

The RNA-Interference industry comprising of various key players such as Alnylam Pharmaceuticals Inc., Benitec BioPharma, Ionis Pharmaceuticals Inc., Sirnaomics Ltd., Switch Therapeutics, Silence Therapeutics PLC, Arrowhead Pharmaceuticals Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim, and Novartis.